| 1.29 -0.05 (-3.73%) | 02-20 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.23  |
1-year : | 2.69 |
| Resists | First : | 1.91 |
Second : | 2.3 |
| Pivot price | 1.57 |
|||
| Supports | First : | 1.27 |
Second : | 1.06 |
| MAs | MA(5) : | 1.37 |
MA(20) : | 1.72 |
| MA(100) : | 1.99 |
MA(250) : | 3.13 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 3.5 |
D(3) : | 5.2 |
| RSI | RSI(14): 37.2 |
|||
| 52-week | High : | 5.92 | Low : | 1.25 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ STIM ] has closed above bottom band by 19.4%. Bollinger Bands are 15% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.36 - 1.37 | 1.37 - 1.37 |
| Low: | 1.26 - 1.27 | 1.27 - 1.28 |
| Close: | 1.27 - 1.29 | 1.29 - 1.31 |
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
Sat, 14 Feb 2026
Neuronetics (STIM) Is Down 9.0% After Turning Cash-Flow Positive On NeuroStar Demand Has The Bull Case Changed? - Sahm
Wed, 11 Feb 2026
Neuronetics (STIM) Stock Rises 41% After Hours: What's Going On? - Benzinga
Tue, 10 Feb 2026
Neuronetics (STIM) Reports Positive Cash Flow Amid Strong Demand - GuruFocus
Tue, 10 Feb 2026
Neuronetics lifts 2025 revenue 99%, books positive Q4 operating cash flow - Stock Titan
Wed, 07 Jan 2026
There's No Escaping Neuronetics, Inc.'s (NASDAQ:STIM) Muted Revenues Despite A 25% Share Price Rise - simplywall.st
Wed, 17 Dec 2025
Neuronetics (NASDAQ:STIM) adds US$25m to market cap in the past 7 days, though investors from five years ago are still down 83% - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 68 (M) |
| Shares Float | 39 (M) |
| Held by Insiders | 15.5 (%) |
| Held by Institutions | 61.9 (%) |
| Shares Short | 7,160 (K) |
| Shares Short P.Month | 6,710 (K) |
| EPS | -0.83 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.4 |
| Profit Margin | -34.3 % |
| Operating Margin | -19.7 % |
| Return on Assets (ttm) | -21.3 % |
| Return on Equity (ttm) | -219 % |
| Qtrly Rev. Growth | 101.3 % |
| Gross Profit (p.s.) | 0.96 |
| Sales Per Share | 1.89 |
| EBITDA (p.s.) | -0.5 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -30 (M) |
| Levered Free Cash Flow | -17 (M) |
| PE Ratio | -1.56 |
| PEG Ratio | 0 |
| Price to Book value | 3.22 |
| Price to Sales | 0.68 |
| Price to Cash Flow | -2.96 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|